Bevacizumab plus Capecitabine versus Capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Authors
Cunningham, DLang, I
Marcuello, E
Lorusso, V
Ocvirk, J
Shin, D
Jonker, D
Osborne, S
Andre, N
Waterkamp, D
Saunders, Mark P
Affiliation
Royal Marsden Hospital, London, UK.Issue Date
2013-10
Metadata
Show full item recordAbstract
Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorectal cancer.Citation
Bevacizumab plus Capecitabine versus Capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. 2013, 14 (11):1077-85 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(13)70154-2PubMed ID
24028813Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(13)70154-2